AGN to raise money for AGN Neuro subsidiary Algernon NeuroScience, a wholly owned subsidiary of Algernon Pharmaceuticals (AGN.c AGNPF) has qualified its Form 1-A offering statement filed with the U.S. Securities and Exchange Commission under a Tier II Regulation A+ offering.
AGN Neuro will be offering up to 37.5% of its common shares at $1/share.
The capital raised will be used for research and development costs related to the completion of the Phase 1 DMT study which is currently underway as well as Phase 2a stroke and traumatic brain injury studies
https://ca.finance.yahoo.com/news/algernon-neuroscience-announces-u-sec-110000416.html